Amikacin Pharmacokinetic-Pharmacodynamic (PK-PD) Analysis in Pediatric Cancer Patients.

about

Amikacin Pharmacokinetic-Pharmacodynamic (PK-PD) Analysis in Pediatric Cancer Patients.

Item

http://www.wikidata.org/entity/Q48528055

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Amikacin Pharmacokinetic-Pharmacodynamic (PK-PD) Analysis in Pediatric Cancer Patients.

@en

Amikacin Pharmacokinetic-Pharmacodynamic

@nl

type

Item

label

Amikacin Pharmacokinetic-Pharmacodynamic (PK-PD) Analysis in Pediatric Cancer Patients.

@en

Amikacin Pharmacokinetic-Pharmacodynamic

@nl

prefLabel

Amikacin Pharmacokinetic-Pharmacodynamic (PK-PD) Analysis in Pediatric Cancer Patients.

@en

Amikacin Pharmacokinetic-Pharmacodynamic

@nl

P1476

Amikacin Pharmacokinetic-Pharmacodynamic (PK-PD) Analysis in Pediatric Cancer Patients.

@en

P2093

Ali A Alhadab

http://www.w3.org/2001/XMLSchema#string

Richard C Brundage

http://www.w3.org/2001/XMLSchema#string

P2860

Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models.

Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint

Population pharmacokinetic study of amikacin administered once or twice daily to febrile, severely neutropenic adults

Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock

Nonparametric population pharmacokinetic analysis of amikacin in neonates, infants, and children.

The antibiotic resistance crisis: part 1: causes and threats.

Pharmacodynamics of ceftazidime administered as continuous infusion or intermittent bolus alone and in combination with single daily-dose amikacin against Pseudomonas aeruginosa in an in vitro infection model.

Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: distribution in tissue.

Pharmacodynamic effects of extended dosing intervals of imipenem alone and in combination with amikacin against Pseudomonas aeruginosa in an in vitro model.

Optimizing the initial amikacin dosage in adults.

P31

scholarly article

P356

10.1128/AAC.01781-17

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Mariam A Ahmed

P577

2018-01-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29358293

http://www.w3.org/2001/XMLSchema#string

P932

5913936

http://www.w3.org/2001/XMLSchema#string